Physician profile
Ravinder Singh
NPI 1184648990
$56,399.15
in general payments reported to CMS, 2019-2025
35 companies · $7,185 in 2025
The $7,185 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $10K · 2021: $6,496 · 2022: $790 · 2023: $1,417 · 2024: $9,999 · 2025: $7,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $3,161 · Travel and Lodging: $870 · Consulting Fee: $490 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,903.60 |
| Food and Beverage | $3,160.78 |
| Travel and Lodging | $869.75 |
| Consulting Fee | $490.00 |
| Education | $175.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34,952.47 | 2019-2023 | Emgality, Reyvow, Amyvid |
| Teva Pharmaceuticals USA, INC. | $17,037.77 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,239.24 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Ucb, INC. | $540.53 | 2019-2023 | |
| Allergan, INC. | $442.31 | 2019-2020 | |
| Lundbeck LLC | $265.32 | 2023-2025 | Vyepti |
| Neurelis, INC. | $208.71 | 2020-2024 | Valtoco |
| Upsher-Smith Laboratories LLC | $176.30 | 2019-2022 | |
| Pfizer INC. | $168.71 | 2021-2025 | |
| Amgen INC. | $168.40 | 2019-2021 | |
| Sk Life Science, INC. | $133.07 | 2020-2023 | |
| Impel Pharmaceuticals INC. | $104.16 | 2023 | Trudhesa |
| Zyla Life Sciences, INC. | $84.70 | 2019-2020 | |
| Axsome Therapeutics, INC. | $83.02 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $72.27 | 2023-2024 | Nuplazid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $71.60 | 2024-2025 | Rexulti |
| Mdd US Operations, LLC | $71.07 | 2019 | |
| Amneal Pharmaceuticals LLC | $64.97 | 2019-2021 | |
| Eisai INC. | $43.93 | 2020-2021 | |
| Biogen, INC. | $43.18 | 2021 | |
| Csl Behring | $42.47 | 2020 | |
| Shire North American Group INC | $41.84 | 2019 | |
| Genzyme Corporation | $37.35 | 2023 | |
| Neurocrine Biosciences, INC. | $33.61 | 2023 | Ongentys, Ingrezza |
| Mallinckrodt Hospital Products INC. | $33.17 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $32.91 | 2025 | |
| Assertio Therapeutics, INC. | $31.71 | 2020 | |
| Novartis Pharmaceuticals Corporation | $31.34 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $24.53 | 2025 | Quviviq |
| Arbor Pharmaceuticals, INC. | $23.42 | 2022 | |
| Tanabe Pharma America, INC. | $23.13 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $19.66 | 2021 | |
| Genentech USA, INC. | $19.01 | 2025 | Ocrevus Zunovo |
| Sunovion Pharmaceuticals INC. | $18.98 | 2019 | |
| Currax Pharmaceuticals LLC | $14.29 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.